Switching from originator to biosimilar infliximab – real world data of a prospective 18 months follow-up of a single-centre IBD population

References

• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462–2476.
   PubMed Web of Science ®Google Scholar
• van der Valk ME, Mangen M-JJ, Severs M, et al. Evolution of costs of inflammatory bowel disease over two years of follow-up. PLoS One. 2016;11:e0142481.
   PubMed Web of Science ®Google Scholar
• Severs M, Oldenburg B, van Bodegraven AA, et al. The economic impact of the introduction of biosimilars in inflammatory bowel disease. J Crohns Colitis. 2017;11:289–296.
   PubMed Web of Science ®Google Scholar
• Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. Eccojc. 2017;11:26–34.
   Web of Science ®Google Scholar
• Buer L, Hoivik ML, Medhus AW, et al. Does the introduction of biosimilars change our understanding about treatment modalities for inflammatory bowel disease? Dig Dis. 2017;35:74–82.
   PubMed Web of Science ®Google Scholar
• Husereau D, Feagan B, Selya-Hammer C. Policy options for infliximab biosimilars in inflammatory bowel disease given emerging evidence for switching. Appl Health Econ Health Policy. 2018;14:1–10.
   PubMed Web of Science ®Google Scholar
• Buer LCT, Moum BA, Cvancarova M, et al. Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. J Crohns Colitis. 2017;11:297–304.
   PubMed Web of Science ®Google Scholar
• Avila-Ribeiro P, Fiorino G, Danese S. The experience with biosimilars of infliximab in inflammatory bowel disease. Curr Pharm Des. 2017;23:11.
   PubMed Web of Science ®Google Scholar
• Smits LJT, Grelack A, Derikx L, et al. Long-term clinical outcomes after switching from Remicade((R)) to Biosimilar CT-P13 in inflammatory bowel disease. Dig Dis Sci. 2017;62:3117–3122.
   PubMed Web of Science ®Google Scholar
• Schmitz EMH, Boekema PJ, Straathof JWA, et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther. 2018;47:356–363.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn’s disease activity and Harvey-Bradshaw indices in assessing Crohn’s disease severity. Clin Gastroenterol Hepatol. 2010;8:357–363.
   PubMed Web of Science ®Google Scholar
• Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660–1666.
   PubMed Web of Science ®Google Scholar
• Kristensen V, Klepp P, Cvancarova M, et al. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin. J Crohn’s Colitis. 2015;9:164–169.
   Google Scholar
• Organization WH. Iron deficiency anemia assessment, prevention and control a guide for programme managers. Report. 2011.
   Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut. 2009;58:492–500.
   PubMed Web of Science ®Google Scholar
• Arguelles-Arias F, Guerra Veloz MF, Perea Amarillo R, et al. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results. Eur J Gastroenterol Hepatol. 2017;29:1290–1295.
   PubMed Web of Science ®Google Scholar
• Razanskaite V, Bettey M, Downey L, et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J Crohns Colitis. 2017;11:690–696.
   PubMed Web of Science ®Google Scholar
• Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389:2304–2316.
   PubMed Web of Science ®Google Scholar
• Boone NW, Liu L, Romberg-Camps MJ, et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol. 2018;74:656–661.
   PubMed Web of Science ®Google Scholar
• Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501–508.
   PubMed Web of Science ®Google Scholar
• Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review. Eccojc. 2015;9:806–815.
   Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: Diagnosis and medical management. Eccojc. 2017;11:3–25.
   Web of Science ®Google Scholar
• Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohn's Colitis. 2017;11:769–784.
   Google Scholar
• Thomas SS, Borazan N, Barroso N, et al. Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis. BioDrugs. 2015;29:241–258.
   PubMed Web of Science ®Google Scholar
• Ben-Horin S, Heap GA, Ahmad T, et al. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications? Expert Rev Gastroenterol Hepatol. 2015;9(Suppl 1):27–34.
   PubMedGoogle Scholar
• Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2018;390:2779–2789.
   PubMed Web of Science ®Google Scholar
• Roblin X, Boschetti G, Duru G, et al. Distinct thresholds of infliximab trough level are associated with different therapeutic outcomes in patients with inflammatory bowel disease: a prospective observational study. Inflamm Bowel Dis. 2017;23:2048–2053.
   PubMed Web of Science ®Google Scholar
• Hoivik ML, Reinisch W, Cvancarova M, et al. Anaemia in inflammatory bowel disease: a population-based 10-year follow-up. Aliment Pharmacol Ther. 2014;39:69–76.
   PubMed Web of Science ®Google Scholar